Alessandro Martorana is an expert in Neurology at Policlinico Tor Vergata (Italy). As of September 2026, ScienceLeadR ranks Alessandro Martorana in the top 1% of experts worldwide for Alzheimer Disease, Dementia and Neurocognitive Disorders. Alessandro Martorana has authored 186 publications, the most recent in 2026, and is an investigator in 5 clinical trials. SLR score: 700 (community average: 125). How the SLR is computed.

LeadR Profile

Alessandro Martorana Policlinico Tor Vergata Italy
700 ScienceLeadR Reputation 700
Network Map

Neurology

Subspecialties: Psychiatry - Nuclear Medicine - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2001 - 2026

Source: PubMed

Policlinico Tor Vergata

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 186

Citations

Citations: 5 859 1st author: 18 Last author: 38 Unique author: 3


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
From network observation to network intervention in Alzheimer's disease.
PMID 42802939 — alzheimer disease, neurology
Brain20260
Diagnosis and management of mild cognitive impairment and mild Alzheimer's disease dementia: Findings from an Italian real-world survey.
PMID 42803713 — research design, dementia, diagnostic techniques and procedures, alzheimer disease, cognitive dysfunction, biomarkers, aged, cognition disorders, diagnosis, therapeutics
J Alzheimers Dis20260
Reconstruction-dependent differences in brain [18F]FDG PET: a large-scale same-acquisition comparison of Q.Clear and VUE Point FX.
PMID 42678670 — radiotherapy, brain, fluorodeoxyglucose f18
Ann Nucl Med20260
Cerebrovascular reactivity and plasma p-tau181 in Alzheimer's disease: Insights into APOE-related vascular phenotypes.
PMID 42388533 — alzheimer disease, phenotype, biomarkers, genotype, apolipoproteins e, plasma
Alzheimers Dement (N Y)20260
Plasma phosphorylated tau biomarkers map onto [^18F]FDG PET hypometabolism: a voxel-wise study in a clinical cohort with CSF-confirmed AD subgroup analysis.
PMID 42191948 — biomarkers, fluorodeoxyglucose f18, cerebellum, nuclear medicine, plasma
Eur J Nucl Med Mol Imaging20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Chair: 1 Study Director: 1

By phase:

N/A 2
Phase 2 2
Phase 3 1

By status:

Completed 5

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 2
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map